New biomarker tests can enable early diagnosis and prompt treatment of symptoms associated with synucleinopathies, according ...

Keywords: Multiple system atrophy, autonomic symptoms, autonomic function tests ... Our in-house editorial team will contact you to talk about your idea and whether you’d like to edit the topic. If ...

Background Multiple system atrophy (MSA) is a progressive neurodegenerative disorder of unknown etiology, manifesting as combination of parkinsonism, cerebellar syndrome and dysautonomia.

ONO-2808 is under clinical development by Ono Pharmaceutical and currently in Phase II for Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration). According to GlobalData, ...

Objectives: The differential diagnosis between typical idiopathic Parkinson’s disease (PD) and the striatonigral variant of multiple system atrophy (MSA-P) is often difficult because of the presence ...

To clarify the progression of autonomic symptoms and functional deterioration in pure autonomic failure (PAF), particularly in comparison with multiple system atrophy (MSA). Methods: The investigation ...

Dysautonomia can be difficult to diagnose, in part because symptoms are linked to a range of health issues. Some causes are common, such as neuropathies that occur with diabetes. Others are rare ...

Your immune system's attack on myelin changes how nerve signals are transmitted in the body. No two people experience multiple sclerosis (MS) in the same way, though an early episode called clinically ...

Value-based agreements come with risks and benefits, but a health system ... patients with multiple sclerosis. A cross-sectional, prospective study found that gray matter atrophy was more ...

Multiple sclerosis (MS ... They are very different conditions, but they sometimes share similar symptoms. Both conditions require a variety of medical tests for a diagnosis.

—Newborn screening for spinal muscular atrophy allows for earlier diagnosis in preterm infants, leading to earlier use of disease-modifying therapies, in the presymptomatic stage, and better ...